Edition:
United Kingdom

John Miller

Roche lifts 2019 sales view again as Chinese demand soars

16 Oct 2019

ZURICH Swiss drugmaker Roche lifted its 2019 sales target on Wednesday for the third time this year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation's annual deaths.

Roche billionaire board member says short-term profit hunger 'destroyed the planet'

10 Oct 2019

GENEVA A member of Swiss drugmaker Roche's controlling family said on Wednesday that short-term profit maximization has "destroyed the planet" and the world needs a new breed of capitalism putting long-term interests first.

Novartis gets FDA boost in crowded eye drug market

08 Oct 2019

ZURICH Novartis's anti-blindness medicine Beovu has become the latest eye drug to win U.S. Food and Drug Administration approval, giving the Swiss drugmaker a boost in the increasingly competitive market for eye problems among an aging population.

SNB's Maechler touts loose money policy amid global tumult

02 Oct 2019

ZURICH Trade wars, Brexit and the simmering Iran conflict are fanning the flames of global uncertainty, stifling industry's readiness to make investments needed to spur productivity, a Swiss National Bank (SNB) policymaker said on Wednesday.

Sunrise's UPC takeover fight grinds on as Freenet spurns concession

30 Sep 2019

ZURICH Sunrise Communications slashed the size of a rights offer but this failed to secure the support of a major shareholder for its 6.3 billion Swiss franc ($6.35 billion) purchase of Liberty Global's Swiss UPC unit.

Sunrise plan to buy Liberty Global's UPC gets anti-trust green light

26 Sep 2019

ZURICH The Swiss anti-trust authority has approved Sunrise Communications' 6.3 billion Swiss franc ($6.36 billion) takeover of Liberty Global's UPC business, setting up a showdown between the telecoms company and foes of the deal.

Swiss watchdog pursues China's HNA over Dufry reporting

25 Sep 2019

ZURICH Switzerland's markets supervisor said on Wednesday it will lodge a criminal complaint against Chinese conglomerate HNA Group for an alleged "serious breach" of disclosure rules over a stake it once held in duty free group Dufry .

British baby's death not due to SMA gene therapy - Novartis

19 Sep 2019

ZURICH A British baby's death this year after getting Novartis's gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment's risks.

World News